Market research
MBRX Moleculin Biotech Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 12M
- P/E ratio
- 0.04
- Dividend yield
- Not available
- Beta
- 1.83
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US60855D4088
- Market cap
- 12M
- P/E ratio
- 0.04
- Dividend yield
- Not available
- Beta
- 1.83
About
About Moleculin Biotech Inc
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MBRX discussion.
5 years, 4 months ago
Moleculin Biotech, Inc is currently in a long term downtrend where the price is trading 21.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Moleculin Biotech, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 357.1% to $-17M since the same quarter in the previous year.
Finally, its free cash flow grew by 33.0% to $-3M since the same quarter in the previous year.
Based on the above factors, Moleculin Biotech, Inc gets an overall score of 2/5.